KB-1389

Ixekizumab

33701

Background of Ixekizumab

Ixekizumab, a humanized monoclonal antibody belonging to the immunoglobulin G subclass 4 (IgG4), targets interleukin-17A (IL-17A) by hindering its interaction with the IL-17A receptor. Given IL-17A's crucial involvement as a pro-inflammatory cytokine in inciting inflammation and orchestrating immune responses, the blockade of its effects proves advantageous in managing inflammatory conditions. Notably, IL-17A's association with various autoimmune diseases, such as Rheumatoid Arthritis and plaque psoriasis, underscores its significance in disease pathogenesis. By neutralizing IL-17A, ixekizumab manifests as a promising therapeutic agent in ameliorating the symptoms and addressing the underlying mechanisms implicated in these autoimmune disorders.

Specifications

Catalog Number	KB-1389
Antibody Name	Ixekizumab
Isotype	Human IgG1,kappa
FC Muations	S228P/K447Del
Target	IL17A
Species Reactivity	Human
Host Cell Line	EXPI CHO
Purification Method	Affinity purified
Concentration	>2 mg/mL
Formulation	50 mM sodium citrate,150mM NaCl,pH5.5
Purity	>95% by SDS-PAGE and SEC-HPLC
Validation	ELISA
Endotoxin Level	<0.2 EU/mg as determined by the LAL method
Sterility	0.2μm filtered
Storage	It is recommended that the protein should be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
Stability	Stable for twelve months from date of receipt when stored at -20°C to -80°C; Stored at 2-8°C for one month without detectable loss of activity.

Characterization

Application

References

Genovese MC, Van den Bosch F, Roberson SA, Bojin S, Biagini IM, Ryan P, Sloan-Lancaster J: LY2439821, a humanized anti-interleukin-17 monoclonal antibody, in the treatment of patients with rheumatoid arthritis: A phase I randomized, double-blind, placebo-controlled, proof-of-concept study. Arthritis Rheum. 2010 Apr;62(4):929-39.
Bush KA, Farmer KM, Walker JS, Kirkham BW: Reduction of joint inflammation and bone erosion in rat adjuvant arthritis by treatment with interleukin-17 receptor IgG1 Fc fusion protein. Arthritis Rheum. 2002 Mar;46(3):802-5.